October 22, 2018 / 5:29 AM / in 25 days

BRIEF-Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis

Oct 22 (Reuters) - GALAPAGOS NV:

* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS

* FINCH 2 STUDY RESULTS DEMONSTRATE SIGNIFICANT IMPROVEMENT IN RHEUMATOID ARTHRITIS SIGNS, SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE

* DATA SUGGEST FILGOTINIB HAS A POTENTIAL ROLE IN ADDRESSING IMPORTANT UNMET NEEDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

* POSITIVE EFFICACY DATA FROM FINCH 2 WERE PREVIOUSLY ANNOUNCED IN SEPTEMBER 2018

* ADDITIONAL FINCH 2 DATA TO BE PRESENTED INCLUDE POSITIVE RESULTS ACROSS SEVERAL PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE MEASURES

* FILGOTINIB DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH EARLIER CLINICAL TRIALS

Source text for Eikon:

Further company coverage:, (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below